Safety of CRIS100 on Treatment Spinal Cord Injury

NCT ID: NCT05739734

Last Updated: 2026-02-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-04-30

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to test CRIS100 treatment in participants with acute thoracic spinal cord injury. The main questions it aims to answer are:

* safety of CRIS100
* efficacy of CRIS100

Participants will receive 100 mcg CRIS100 in the epicenter of the spinal injury, within 72 hours of the trauma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants with complete spinal cord injury between T2 and T10 (ASIA A, according to ISNCSCI, 2019 revision) and:

* occurred less than 72 hours ago
* with surgical indication
* bulbocavernous reflex present
* who can receive treatment with CRIS100 within 72 hours after the trauma (preferably within 24 hours)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thoracic Spinal Cord Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CRIS100 treatment

Administration of a single dose of CRIS100

Group Type EXPERIMENTAL

CRIS100

Intervention Type DRUG

local application of CRIS100

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CRIS100

local application of CRIS100

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signature of the Free and Informed Consent Term by the participant or legal guardian
* Age between 18 and 70 years old;
* Thoracic spinal cord injury between T2 and T10, with surgical indication, occurred less than 72 hours before surgery;
* Presence of bulbo cavernosum reflex;
* Patients with a lesion classified as ASIA A according to the ISNCSCI (2019 revision);

Exclusion Criteria

* Absence of bulbocavernous reflex up to 72 hours after the trauma.
* Presence of severe brain trauma.
* Patients with lesions above T2 or below T10.
* More than one site of spinal cord injury.
* History of alcohol or illicit drug abuse, as defined by DSM 5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition or later).
* Patients who need permanent mechanical respiratory support.
* Polytraumatized patients who, in the investigator's assessment, compromise the neurological evolution.
* Neurological diseases or functional dependence of any etiology prior to the trauma.
* Any other comorbidity that, at the discretion of the investigator, makes it impossible to include the patient in the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cristália Produtos Químicos Farmacêuticos Ltda.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jorge B Afiune, MD

Role: CONTACT

+55 11 98364 5551

Patricia C Bombarda, Post Graduate

Role: CONTACT

+551146135119

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRT100

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Spinal Cord Neuromodulation for Spinal Cord Injury
NCT02313194 ACTIVE_NOT_RECRUITING PHASE1/PHASE2
Spinal Cord Stimulation and Training
NCT05472584 RECRUITING NA
Cethrin in Acute Cervical Spinal Cord Injury
NCT02053883 WITHDRAWN PHASE2/PHASE3
Cervical Transcutaneous SCS for TBI
NCT07147816 RECRUITING NA